KINETA, INC.

Basic Information

219 Terry Ave N. Suite 300
SEATTLE, WA, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 809832558
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Agonists of the RIG-I Innate Immune Pathway

    Amount: $2,836,489.00

    DESCRIPTION (provided by applicant): Through Phase I studies, we have identified five lead small molecule compounds with drug-like properties that activate innate immune response pathways and inhibit ...

    SBIR Phase II 2011 Department of Health and Human Services
  2. Development of Kv1.3 channel blocker ShK-186 as a therapy for multiple sclerosis

    Amount: $599,443.00

    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) affects approximately 400,000 Americans and constitutes a progressive, disabling disease for which current therapies are inadequate. This a ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. Agonists of the RIG-I Innate Immune Pathway

    Amount: $585,307.00

    DESCRIPTION (provided by applicant): There is a tremendous commercial demand for new antiviral products with novel mechanisms of action and which target a broad spectrum of viruses. Most previous and ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government